RTP Mobile Logo
Fall Oncology Nursing Series: Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia and Lymphomas — Session 2 (Webinar Video Proceedings)
Released November 2021

Proceedings from a series of 6 fall webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Dr Jeremy Abramson and Ms Elizabeth Zerante. Published November 24, 2021. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia and lymphomas.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with chronic lymphocytic leukemia and lymphomas.

    LEARNING OBJECTIVES

    • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational products.
    • Evaluate the biologic basis for the investigation of CAR T-cell therapy for relapsed/refractory chronic lymphocytic leukemia (CLL), and educate patients about the potential clinical role of this strategy.
    • Recognize common adverse events associated with FDA-approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for complications.
    • Recall ongoing research evaluating CAR T-cell-based approaches for CLL and lymphomas, and counsel appropriate patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    Audio Program: This educational activity for 1.75 contact hours is provided by RTP during the period of November 2021 through November 2022.

    This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.25 contact hours is provided by RTP during the period of November 2021 through November 2022.

    This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSCART2021/MTP2/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2021/MTP2/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSCART2021/MTP2/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2021/MTP2/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSCART2021/MTP2.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Jeremy Abramson, MD
    Director, Center for Lymphoma
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc.

    Elizabeth Zerante, MS, AGACNP-BC
    APN Inpatient Hematopoietic Cellular Therapy Service
    University of Chicago Medicine
    Chicago, Illinois

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Bristol-Myers Squibb Company.

    Release date: November 2021
    Expiration date: November 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):